Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee Buys 16,542 Shares

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee purchased 16,542 shares of the stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the acquisition, the chief executive officer now owns 1,496,175 shares of the company’s stock, valued at $23,938,800. The trade was a 1.12 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Aardvark Therapeutics Price Performance

Shares of AARD opened at $14.90 on Thursday. Aardvark Therapeutics, Inc. has a 52 week low of $11.55 and a 52 week high of $16.48.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.